REVIEW

Pulmonary Rehabilitation Programmes Within Three Days of Hospitalization for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

Dong Zhang (b)¹⁻³ Hailong Zhang ¹⁻³ Xuanlin Li¹⁻³ Siyuan Lei¹⁻³ Lu Wang ¹⁻³ Wen Guo¹⁻³ Jiansheng Li¹⁻³

¹Co-Construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan & Education Ministry of P.R. China, Henan University of Chinese Medicine, Zhengzhou, 450046, People's Republic of China; ²Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan University of Chinese Medicine, Zhengzhou, 450046, People's Republic of China; ³Department of Respiratory Diseases, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, 450003, People's Republic of China

Correspondence: Jiansheng Li Tel/Fax +86-371-65676568 Email li_js8@163.com **Objective:** To evaluate the efficacy and safety of early pulmonary rehabilitation (PR) (ie, <3 days of hospitalization) in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

Methods: Embase, Web of Science, PubMed and Cochrane Library were searched from their inception to 1 April 2021. Randomized controlled trials were included if they observed the efficacy of early PR in AECOPD patients. Study selection, data extraction, risk of bias and quality of evidence were assessed by two researchers independently. Assessment of the risk of bias and eidence quality were evaluated by the Cochrane Collaboration's tool and Grading of Recommendations, Assessment, Development and Evaluation system, respectively.

Results: Fourteen trials (829 participants) were identified. Significant improvement was found in the 6-minute walk distance (6MWD; mean difference (MD): 69.64; 95% CI: 40.26 to 99.01; Z = 4.65, P < 0.0001, low quality). In the subgroup analysis, the exercise-training group showed marked improvement (MD: 96.14; 95% CI: 20.24 to 172.04; Z = 2.48, P = 0.001). The Saint George's Respiratory Questionnaire (SGRQ) total score was low (MD: -12.77; 95% CI: -16.03 to -9.50; Z = 7.67, P < 0.0001, moderate quality). Significant effects were not found for the duration of hospital stay, quadriceps muscle strength or five times sit to stand test. Only one serious adverse event was reported in experimental group, which was not associated with early PR.

Conclusion: PR initiated <3 days of hospitalization may increase exercise capacity and improve quality of life, but the results should be interpreted prudently and dialectically, and the role of early PR in AECOPD needs further exploration.

Keywords: chronic obstructive pulmonary disease, acute exacerbation, pulmonary rehabilitation, meta-analysis

Introduction

Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease. It carries a high prevalence and is associated with disability and mortality.^{1,2} COPD is a major public-health challenge facing society today.^{3,4}

An acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is defined as acute exacerbation of respiratory symptoms which results in additional therapy.⁵ AECOPD can influence disease progression as well as the prevalence of hospitalization and readmission to hospital.^{3,6–8} More than 20% of AECOPD

patients will be hospitalized again with the same diagnosis within 30 days, which increases the economic burden of patients significantly.⁹ COPD exacerbations can accelerate disease progression by contributing to a decline in lung function of >25%.¹⁰ Moreover, the long-term prognosis of severe COPD necessitating hospitalization is poor, with 5-year mortality of ~50%.¹¹ Therefore, reducing the impact of acute exacerbation and preventing its recurrence is an important treatment goal of AECOPD.^{3,12}

Systemic corticosteroids, antibiotics and short-acting bronchodilators are the cornerstones of management of COPD exacerbations. These agents can significantly improve clinical symptoms, accelerate disease recovery, and improve gas exchange.^{13,14} Although these drug therapies are efficacious, the search for better interventions is ongoing. In recent years, non-drug therapy has garnered increasing attention.

Pulmonary rehabilitation (PR) is a comprehensive intervention that include, but are not limited to, education, exercise training, and behavior change,¹⁵ has shown well-established benefits in patients with stable COPD. PR is considered first-line nonpharmacologic treatment for COPD.³ Several studies have indicated that PR for AECOPD patients is safe and efficacious, and can improve clinical symptoms, exercise tolerance and quality of life (QoL).¹⁶⁻³¹ It has been postulated that comprehensive PR measures should be implemented immediately after acute exacerbation, which can increase exercise capacity and QoL.^{15,32} Of relevant studies, ~57% have been conducted during hospitalization, 42% of which started within 48 h of hospital admission.³³ However, the starting time of PR is in a wide range, from admission to 2-3 weeks after discharge, which hampered judgement of the exact time to initiate PR.³³ Moreover, whether comprehensive PR^{15,33} during hospitalization is safe and clinically effective is still controversial.^{6,34} This controversy may be related to six main factors: (i) different PR strategies have different effects;³³ (ii) the time window for starting PR differs;³³ (iii) the safety of initiating PR during hospitalization;⁶ (iv) insufficient support for medical equipment:³⁵ (v) potential comorbidity instability and the contentious issue of using energy resources for exercise during early illness; (vi) different outcomes and outcome measures are used.³⁶ Given the above considerations, we aimed to explore the efficacy of early PR for AECOPD patients <3 days of hospital admission to provide evidence for clinical practice.

Materials and Methods

This review was conducted in strict accordance with the Cochrane Handbook for Systematic Reviews of Interventions³⁷ and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)³⁸ guidelines. The protocol for this review has been registered in the International Prospective Register of Systematic Reviews (PROSPERO) and the registry number is CRD42021242284.

Search Strategy

A literature search was conducted on 29 December 2020 on four databases (PubMed, Embase, Web of Science, Cochrane Library) and the results were updated on 1 April 2021. To obtain comprehensive results, systematic search strategies were formulated according to the characteristics of each database. The detailed retrieval strategies and steps are presented in the Supplementary Materials <u>Appendix 1</u>. Furthermore, the reference lists of the retrieved articles and relevant systematic reviews were scanned manually for other potentially eligible studies.

Inclusion Criteria

Articles meeting all of the following criteria were included: (i) the study population was AECOPD patients (based on GOLD guidelines or expert consensus); (ii) the intervention was $PR^{15,33}$ (began <3 days of hospitalization) and at least one of the following interventions was included: exercise training, inspiratory-muscle training, neuromuscular electrical stimulation, nutrition support and self-management; (iii) the comparison was between PR and control (ie, conventional therapy, standard care, no treatment and sham exercise); (iv) the primary outcomes were exercise tolerance (measured by the 6-minute walk distance (6MWD)) and QoL (Saint George's Respiratory Questionnaire (SGRQ) total score); (v) the secondary outcomes were the duration of hospital stay (DoHS), quadriceps muscle strength (QMS), five times sit to stand test (5STS) and adverse events; (vi) the study design was a randomized controlled trial (RCT).

Exclusion Criteria

The exclusion criteria were: (i) patients had AECOPD combined with other chronic respiratory diseases (asthma, pulmonary fibrosis, bronchiectasis); (ii) conference abstracts, study protocols and grey literature; (iii) duplicate publications; (iv) study design was not RCTs

(observational, cohort, retrospective as well as case control studies).

Study Selection

Before the article was screened, we first selected 50 articles for pre-screening, then determined the unified screening criteria, and finally conducted formal screening. Same for data extraction and assessment of risk of bias. Study selection was conducted independently by D Zhang, L Wang, W Guo and SY Lei in two phases to screen which articles were suitable. First, duplicate and irrelevant studies were discarded after examining the titles and abstracts. Then, the full-text of potentially eligible studies was downloaded and reviewed based on the inclusion and exclusion criteria stated above. Disagreements were resolved by HL Zhang, who acted as an arbiter. If there was still a dispute, our team members would discuss it together and finally reach a consensus. NoteExpress software was used for the study screening, and record the reasons why studies were excluded.

Data Extraction

Data extraction was carried out independently by D Zhang and XL Li from eligible studies using a standardized dataextraction form. The latter was based on the title, author




Figure I Study selection process for this review.

Table I Basic Characteristics of Included Studies	haracteristics:	of Include	d Studies								
First Author Year	Country	Design	Patients N (EG/CG)	Gender (M/F)	Age	Duration of PR	Follow Up	Frequency	Program of EG	CG Group	Outcomes
Vermeeren 2004 ⁴¹	Netherlands	RCTs 2 arms	47(23/24)	EG 14/9 CG 18/6	EG 66.0 ±8.0 CG 65.0 ±10	From the second day of admission to discharge	°Z	Three times a day. 125mL each time	Nutritional support (Nutricia)	Placebo	QMS
Tang 2012 ⁴²	Australia	RCTs 2 arms	32(21/11)	EG 7/14 CG 6/5	EG 70.7 ±10.2 CG 78.0 ±8.8	From the second day of admission to discharge	°Z	Twice a day, 15 minutes each time	Aerobic and resistance exercise	Sputum clearance, mobility assessments, functional training	Adverse events
Greulich 2014 ⁴³	Germany	RCTs 2 arms	49(23/26)	EG 14/6 CG 12/8	EG 66.4 ±9.9 CG70.4 ±10.1	From the second day of admission to discharge	°Z	Once a day, 26 minutes each time	Whole body vibration training, mobilisation to bedside and stand, respiratory therapy, passive muscle movements	Mobilisation to bedside and stand, respiratory therapy, passive muscle movements	6MWD, SGRQ, DoHS, 5 STS, adverse events
Osadnik 2014 ⁴⁴	Australia	RCTs 2 arms	90 (45/45)	EG28/17 CG30/ 15	EG 69.5 ±9.8 CG67.8 ±11.6	From the second day of admission to discharge	6 months	Once a day, 20 minutes each time	PEP therapy	Usual care	DoHS, adverse events
Borges 2014 ⁴⁵	Brazil	RCTs 2 arms	29 (15/14)	EG8/7 CG10/4	EG 64.1 ±12.5 CG67.8 ±9.0	From the third day of admission to discharge	month	Once a day, 2 sets of 8 repetitions each time	Whole-body resistance training	Usual care	DoHS, 6MWD, SGRQ

6MWD, adverse events,	QMS, adverse events	GWWD	DoHS	DoHS, 5 STS	5 STS, QMS, adverse events	DoHS,5 STS, adverse events
Usual care	Usual care	False stimulation	Usual care	Usual care	Usual care	Usual care
Exercise training, relaxation, education, breathing retraining	Cycling exercise	Transcutaneous Electrical Nerve Stimulation	Controlled breathing, range of motion exercises, Resistance exercises	Functional electrostimulation, calisthenic exercises	Functional electrostimulation, cycling exercise	Neuromuscular stimulation, lower limb exercises, self- management
Once a day, 20 minutes each time	Once a day	Once a day, 45 minutes each time	Once a day, 30 to 40 minutes each time	Once a day, 45 minutes each time	Once to two a day, 30 minutes each time	Once a day
No	° Z	° Z	° Z	oZ	° Z	Ž
From the second day of admission to discharge	From the second day of admission to discharge	From the second day of admission to discharge	From the second day of admission to discharge	From the first day of admission to discharge	From the second day of admission to discharge	From the second day of admission to discharge
EG 69.2 ±1.5 CG73.9 ±1.8	EG75.7 ±6.3 CG72.1 ±8.2		EG 72.6 ±9.9 CG71.1 ±9.4	EG63.4 ±11.3 CG64.3 ±8.5	EG70.0 ±7.3 CG68.5 ±8.9	EG71.9 ±9.6 CG68.5 ±8.9
EG60/6 CG23/5	EG22/7 CG20/9	EG28/7 CG26/9	EG54/6 CG24/6	EG21/6 CG10/2	1	,
94 (66/28)	58(29/29)	70(35/35)	90 (60/30)	39(27/12)	48(32/16)	66(44/22)
RCTs 2 arms	RCTs 2 arms	RCTs 2 arms	RCTs 2 arms	RCTs 2 arms	RCTs 2 arms	RCTs 2 arms
China	Spain	Turkey	Spain	Spain	Spain	Spain
He 2015 ⁴⁶	Torres- Sánchez2017 ⁴⁷	Öncü 2017 ⁴⁸	Torres- Sánchez2018 ⁴⁹	Lopez Lopez 2018 ⁵⁰	Lopez Lopez 2019 ⁵¹	Lopez Lopez 2020 ⁵²

First Author Year	Country Design	Design	Patients N (EG/CG)	Gender (M/F)	Age	Duration of PR	Follow Up	Frequency	Program of EG	CG Group	Outcomes
Knaut 2020 ⁵³	Brazil	RCTs 2 arms	26(13/13)	EG9/4 CG8/5	EG66.8 ±9.5 CG69.3 ±13.5	From the third day of admission to discharge	°Z	Twice a day, 15 minutes each time	Aerobic exercise	Usual care	SGRQ, 6MWD, DoHS
Lu 2020 ⁵⁴	China	RCTs 2 arms	72(36/36)		EG67.4 ±7.1 CG68.3 ±6.8	From the second day of admission to 9 weeks	°Z	Three times a day, repeat each action 15 to 20 times each time	Zheng's Supine Rehabilitation Exercise	Usual care	DoHS, 6MWD
Abbreviations: F, female; M, male; E test; DoHS, duration of hospital stay.	male; M, male; EG of hospital stay.	i, experiment	al group; CG, cc	ontrol group;	RCTs, rando	mized controlled	trials; 6MWE), 6-minute walk distance	Abbreviations: F, female; M, male; EG, experimental group; CG, control group; RCTs, randomized controlled trials; 6MWD, 6-minute walk distance; SGRQ, the Saint George's Respiratory Questionnaire; 5 STS, five times sit to stand test; DoHS, duration of hospital stay.	Questionnaire; 5 STS, five	times sit to stand

information, year of publication, country, experimental design, participant characteristics (age, sex, sample size), type and duration of intervention, comparators and outcomes. The outcomes were collected at baseline (<3 days of hospitalization) and before discharge. JS Li resolved any disagreements.

Assessment of Risk of Bias

The Risk of Bias tool³⁷ was used for quality assessment. This tool contains seven items. Before the literature was assessed, we would conduct a training session, then D Zhang and XL Li would assess each study independently to see if it had a "high", "unclear" or "low" risk of bias. If opinions differed, HL Zhang intervened until a consensus was reached.

Statistical Analyses

Review Manager 5.3 (https://training.cochrane.org/onlinelearning/core-software-cochrane-reviews/revman/) was used for meta-analysis.³⁹ The mean difference (MD) was employed for continuous outcomes. The odds ratio (OR) was used for dichotomous outcomes. The 95% confidence interval (CI) was calculated for each outcome. If heterogeneity was absent ($P \ge 0.1$, $I^2 \le 50\%$), the fixed-effect model was used for analyses, otherwise the random-effect model was chosen. In order to reduce heterogeneity and address potential confounding, we conducted a subgroup analysis of 6MWD based on different interventions. Sensitivity analysis was undertaken to estimate the consistency of the results by removing each study separately.

Evidence Assessment

Grading of Recommendations, Assessment, Development and Evaluation (GRADE)⁴⁰ was used to assess the quality of evidence of primary outcomes. Five aspects were focused upon: "risk of bias", "inconsistency", "indirectness", "imprecision", and "publication bias". The quality of evidence was assessed as "high", "moderate", "low" or "very low".

Results

Identification of Studies

A total of 3580 articles were identified through manual searching and electronic searching, of which 1226 were duplicates. Fifty-one articles were considered potentially eligible for further assessment after screening of the title and abstract. After reading the full-text carefully, 37

Table I (Continued)

articles were excluded for the following reasons: (i) meeting abstracts (n = 3), (ii) not RCTs (n = 2); (iii) study protocol (n = 4); (iv) irrelevant outcomes (n = 1); (v) inclusion of participants >3 days after AECOPD onset (n = 27). A list of excluded literature studies and reasons for exclusion are provided in the Supplementary Materials <u>Appendix 2</u>. Finally, 14 studies were included in this review. The process of study selection is shown as Figure 1.

Study Characteristics

Fourteen RCTs^{41–54} from 2004 to 2020 in seven countries were included in this review, of which 57.14% were published in the previous 5 years. The sample size of the experimental group and control group in the included studies was 471 and 358, respectively, with the maximum sample size being 94 and the minimum being 26. The basic characteristics of included studies are shown in Table 1.

Risk of Bias

All included studies were RCTs and had similar characteristics of the study cohort at baseline, and only one study⁴¹ blinded the study protocol from patients. Twelve studies^{42–47,49–54} identified the method of allocation concealment, and the outcome assessment was blinded in six studies.^{42–45,52,54} A detailed assessment of risk of bias is provided in Figure 2A and B.

Effects of Interventions

3.3.1 6-minute walk distance (6MWD)

Six studies^{43,45,46,48,53,54} (319 participants) were included in this part of the meta-analysis. Significant heterogeneity was found ($\chi^2 = 44.24$, P < 0.0001; $I^2 = 89\%$), so a randomeffects model was employed. There was a remarkable improvement on 6MWD (MD: 69.64; 95% CI: 40.26 to 99.01; Z = 4.65, P < 0.0001). In the subgroup analysis, the improvement was more obvious in the exercise-training group (MD: 96.14; 95% CI: 20.24 to 172.04; Z = 2.48, P = 0.01) (Figure 3). The quality of evidence for early PR to improve 6MWD in AECOPD patients was low.

Saint George's Respiratory Questionnaire (SGRQ)

Three studies^{43,45,53} (95 participants) were included in this part of the meta-analysis. Significant heterogeneity was not observed ($\chi^2 = 1.49$, P = 0.47; $I^2 = 0\%$) and a fixed-effects model was chosen. There was a significant treatment effect on the total score of SGRQ (MD: -12.77; 95% CI: -16.03 to -9.50; Z =7.67, P < 0.0001) (Figure 4). The quality of evidence for early PR to reduce the total score of SGRQ in AECOPD patients was moderate.

Duration of Hospital Stay (DoHS)

Eight studies^{43–45,49,50,52–54} (434 participants) provided numerical data for DoHS and were included in this part of the meta-analysis. Significant heterogeneity was not found ($\chi^2 = 6.95$, P = 0.43; $I^2 = 0\%$) and a fixed-effects




Figure 2 Continue.




Figure 2 (A) Risk of bias graph. (B) Risk of bias summary.

model was used. Early PR could not reduce the DoHS (MD: 0.26; 95% CI: -0.08 to 0.61; Z = 1.49, P = 0.14) (Figure 5).

Quadriceps Muscle Strength (QMS)

Three studies^{41,47,51} (149 participants) were included in this part of the meta-analysis. Significant heterogeneity was found ($\chi^2 = 11.80$, P = 0.003; $I^2 = 83\%$) so a random-

effects model was chosen. There was no significant treatment effect on QMS (MD: 17.54; 95% CI: -4.46 to 39.55; Z = 1.56, P = 0.12) (Figure 6).

Five Times Sit to Stand Test (5STS)

Four studies^{43,50–52} (193 participants) were included in this part of the meta-analysis. Significant heterogeneity was not observed ($\chi^2 = 2.46$, P = 0.48; $I^2 = 0\%$) so a fixed-effects model was chosen. A positive influence on reducing 5STS was not documented after PR (MD: -3.83; 95% CI: -8.78 to 1.12; Z = 1.52, P = 0.13) (Figure 7).

Quality of Evidence

The GRADE system was used to evaluate the evidence level of 6MWD and SGRQ. The quality of evidence was low for 6MWD, because of unclear allocation concealment, lack of blinding and high heterogeneity. The quality of evidence was downgraded to moderate for SGRQ because of lack of blinding or unclear allocation concealment. The detail of GRADE evaluation is shown in Table 2.

Adverse Events

Only two of the included studies^{42,44} reported adverse events. Eight patients were involved in 15 adverse events related to PR. Only one patient had a serious adverse event, and this patient had a history of atrial fibrillation. Without medical intervention, the chest pain disappeared and this patient continued to complete the remaining tasks. Other events were nonserious and tolerable.

Sensitivity Analysis

Each article was removed individually and then sensitivity analysis was conducted to ascertain the stability of the results. There were no considerable changes among most of the outcomes. However, a large change was noted for QMS when one study was excluded⁴¹ (Table 3).

Discussion

Our systematic review was based on 14 RCTs involving 829 patients with AECOPD. The meta-analysis was based on 13 RCTs with 791 patients. Compared with the control group, for AECOPD patients, the early-PR group had improved exercise endurance and QoL. Serious adverse events related to early PR were not observed.

	Exp	erimenta	al		Control			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.1.1 All types of inte	erventior	าร							
Borges RC 2014	160	61	15	11	83	14	5.8%	149.00 [95.68, 202.32]	
Greulich T 2014	95.55	120.93	20	-5.12	115.74	20	3.9%	100.67 [27.31, 174.03]	— <u> </u>
He M 2015	49	14.82	66	9.8	20.4	26	11.9%	39.20 [30.58, 47.82]	•
Knaut C 2020	48.1	18.12	30	30	39.3	30	11.2%	18.10 [2.61, 33.59]	-
Lu H 2020	140.5	92.53	36	15.2	79.18	36	7.6%	125.30 [85.52, 165.08]	
Öncü E 2017	96.7	36.13	13	50.5	34.43	13	9.5%	46.20 [19.07, 73.33]	
Subtotal (95% CI)			180			139	50.0%	69.64 [40.26, 99.01]	•
Heterogeneity: Tau ² =	1002.49	; Chi² = 4	4.24, c	df = 5 (F	o < 0.000	01); l² =	= 89%		
Test for overall effect:	Z = 4.65	(P < 0.0	0001)						
1.1.2 Exercise training	ng group)							
Borges RC 2014	160	61	15	11	83	14	5.8%	149.00 [95.68, 202.32]	
Greulich T 2014	95.55	120.93	20	-5.12	115.74	20	3.9%	100.67 [27.31, 174.03]	
Knaut C 2020	48.1	18.12	30	30	39.3	30	11.2%	18.10 [2.61, 33.59]	-
Lu H 2020	140.5	92.53	36	15.2	79.18	36	7.6%	125.30 [85.52, 165.08]	
Subtotal (95% CI)			101			100	28.5%	96.14 [20.24, 172.04]	\bullet
Heterogeneity: Tau ² =	5384.21	; Chi² = 4	3.92, c	df = 3 (F	o < 0.000	01); l² =	= 93%		
Test for overall effect:	Z = 2.48	(P = 0.0	1)						
1.1.3 Exercise training	ng combi	ined with	n inspi	ratory 1	training	group			
He M 2015	49	14.82	66	9.8	20.4	26	11.9%	39.20 [30.58, 47.82]	1.
Subtotal (95% CI)			66			26	11.9%	39.20 [30.58, 47.82]	•
Heterogeneity: Not ap	plicable								

46.20 [19.07, 73.33]

Heterogeneity: Not applicable Test for overall effect: Z = 8.92 (P < 0.00001) 1.1.4 Neuromuscular electrical stimulation group Öncü E 2017 96.7 36.13 13 50.5 34.43 13

Test for subgroup differences: Chi² = 5.83, df = 3 (P = 0.12), I^2 = 48.6%

Subtotal (95% CI) 13 13 9.5% 46.20 [19.07, 73.33] Heterogeneity: Not applicable Test for overall effect: Z = 3.34 (P = 0.0008) Total (95% CI) 278 100.0% 66.45 [48.75, 84.15] 360 Heterogeneity: Tau² = 664.51; Chi² = 88.48, df = 11 (P < 0.00001); l² = 88%

-200 -100 0 100 200 Favours [control] Favours [experimental]

Figure 3 Experimental group versus control group, 6MWD.

Test for overall effect: Z = 7.36 (P < 0.00001)

	Ехр	erimen	tal	c	ontrol			Mean Difference		Меа	n Differei	псе	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, F	ixed, 95%	∕₀ CI	
Borges RC 2014	-10.7	11.8	15	-2.4	19.6	14	7.5%	-8.30 [-20.18, 3.58]					
Greulich T 2014	-28.5	4.57	13	-14.8	4.77	13	82.6%	-13.70 [-17.29, -10.11]					
Knaut C 2020	-6.43	16.68	20	1.95	16.78	20	9.9%	-8.38 [-18.75, 1.99]			-		
Total (95% CI)			48			47	100.0%	-12.77 [-16.03, -9.50]		•			
Heterogeneity: Chi ² = Test for overall effect:		•	· · ·					-	-50 Favours	-25 [experiment	0 al] Favo	25 25 purs[control	50

9.5%

Figure 4 Experimental group versus control group, SGRQ.




Figure 5 Experimental group versus control group, DoHS.

	Exp	eriment	al	С	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI Year	IV, Random, 95% CI
Vermeeren MA 2004	3	8	20	2	9	23	41.0%	1.00 [-4.08, 6.08] 2004	•
Torres-Sánchez I 2017	10.47	33.12	29	-15.17	35.4	29	33.0%	25.64 [8.00, 43.28] 2017	- ∎-
Lopez Lopez L 2020	42.81	70.33	32	9.47	21.63	16	26.0%	33.34 [6.77, 59.91] 2019	
Total (95% CI)			81			68	100.0%	17.54 [-4.46, 39.55]	◆
Heterogeneity: Tau ² = 3	800.84; Ch	i ² = 11.8	30, df =	2 (P = 0	.003); l²	² = 83%	,		-100 -50 0 50 100
Test for overall effect: Z	. = 1.56 (P	9 = 0.12)							Favours [control] Favours [experimental]
igure 6 Experimental gr	oup renot		0						
	·		U					Mean Difference	Mean Difference
	·	eriment SD	al		Control		Weight	Mean Difference IV. Fixed, 95% Cl	Mean Difference IV. Fixed, 95% Cl
	Expe	eriment	al	C	Control SD	Total	Weight	IV, Fixed, 95% Cl	
Study or Subgroup	Expe Mean	eriment SD	al Total	0 <u>Mean</u> 9.99	Control SD 29.09	Total	14.2%	IV, Fixed, 95% Cl -12.16 [-25.30, 0.98]	
Study or Subgroup Greulich T 2014	Expe <u>Mean</u> -2.17	eriment SD 7.24	al <u>Total</u> 20	(<u>Mean</u> 9.99 -3.67	Control SD 29.09 24.81	Total 20	14.2% 10.3%	IV, Fixed, 95% Cl -12.16 [-25.30, 0.98] -7.88 [-23.33, 7.57]	
Study or Subgroup Greulich T 2014 Lopez Lopez L 2018	Expe <u>Mean</u> -2.17 -11.55	eriment <u>SD</u> 7.24 17.11	al <u>Total</u> 20 27	(<u>Mean</u> 9.99 -3.67 -7.79	Control SD 29.09 24.81	Total 20 12 22	14.2% 10.3% 29.8%	IV. Fixed, 95% Cl -12.16 [-25.30, 0.98] -7.88 [-23.33, 7.57] -2.96 [-12.02, 6.10]	
<u>Study or Subgroup</u> Greulich T 2014 Lopez Lopez L 2018 Lopez Lopez L 2019	• <u>Mean</u> -2.17 -11.55 -10.75	7.24 77.11 77.51	al <u>Total</u> 20 27 44	(<u>Mean</u> 9.99 -3.67 -7.79	Control SD 29.09 24.81 17.81	Total 20 12 22	14.2% 10.3% 29.8% 45.7%	IV. Fixed. 95% Cl -12.16 [-25.30, 0.98] -7.88 [-23.33, 7.57] -2.96 [-12.02, 6.10] -0.90 [-8.22, 6.42]	
Study or Subgroup Greulich T 2014 Lopez Lopez L 2018 Lopez Lopez L 2019 Lopez Lopez L 2020 Total (95% CI)	Mean -2.17 -11.55 -10.75 -1	SD 7.24 17.11 17.51 8.46	al <u>Total</u> 20 27 44 32 123	Mean 9.99 -3.67 -7.79 -0.1	Control SD 29.09 24.81 17.81	Total 20 12 22 16	14.2% 10.3% 29.8% 45.7%	IV. Fixed. 95% Cl -12.16 [-25.30, 0.98] -7.88 [-23.33, 7.57] -2.96 [-12.02, 6.10] -0.90 [-8.22, 6.42]	IV. Fixed. 95% Cl
Study or Subgroup Greulich T 2014 Lopez Lopez L 2018 Lopez Lopez L 2019 Lopez Lopez L 2020	• <u>Mean</u> -2.17 -11.55 -10.75 -1 2.46, df =	SD 7.24 17.11 17.51 8.46 3 (P =	al <u>Total</u> 20 27 44 32 123 0.48); I	Mean 9.99 -3.67 -7.79 -0.1	Control SD 29.09 24.81 17.81	Total 20 12 22 16	14.2% 10.3% 29.8% 45.7%	IV. Fixed. 95% Cl -12.16 [-25.30, 0.98] -7.88 [-23.33, 7.57] -2.96 [-12.02, 6.10] -0.90 [-8.22, 6.42]	

Figure 7 Experimental group versus control group, 5 STS.

As one of the most used methods to measure the clinical outcome of COPD, the 6MWD has an important role in evaluating exercise capacity as well as estimating the prognosis and treatment response of COPD patients.^{36,55} In our review, the 6MWD in the early PR group was longer than that in the control group, with an MD of 69.64 m, which exceeded the minimum clinically important difference of 6MWD by 54 m.⁵⁶ However, the quality of evidence was low, which should be interpreted prudently and dialectically. Compared with that in previous studies, the 6MWD was longer in our study, which may be related to the different time window for starting PR. This result suggests that early PR has potential for improving exercise tolerance.²⁷ In the subgroup analysis, improvement in the 6MWD was more remarkable in the exercise-training group, with an MD of 96.14 m. This change demonstrates that, as the cornerstone of PR, exercise training can improve exercise endurance in terms of muscle function. High heterogeneity was found in the included studies, which may be related to the type, intensity and duration of intervention measures.

QoL measurements have become a vital outcome measure in COPD management.⁵⁷ SGRQ, as one of the indicators for evaluating the QoL of patients, can reflect the overall status of the patient.⁵⁸ The higher the SGRQ score, the worse is the QoL related to health. The total score of SGRQ in the early-PR group was lower than that of the control group, with an MD of -12.77 (95% CI, -16.03 to -9.50), and the quality of evidence was moderate. Compared with previous studies, the total score of SGRQ was lower.^{17,18,27} This result implies that PR initiated <3 days of hospitalization can improve the QoL of AECOPD patients significantly.

The DoHS not only reflects disease severity directly, it also indirectly reflects the efficacy of clinical interventions. Eight articles focused on the DoHS as an outcome measure. The DoHS in the PR group was longer than that in the control group (MD = 0.26 days) so early PR did not shorten the DoHS.

Often, patients with COPD have dysfunction and atrophy of skeletal muscle, which not only severely affects function of the lower limbs, it also affects function of the respiratory muscles and aggravates respiratory symptoms.⁵⁹ 5STS and QMS are simple, effective and portable clinical tools that are often used to assess the function, balance and mobility of the lower limbs in older patients.⁶⁰ The 5STS and QMS of the early-PR group were greater compared with those of the control group, and the MD of all AECOPD patients included was -3.83 s and 17.54 N, respectively. However, there was no significant improvement in 5STS or QMS between the two groups. When one study⁴¹ was excluded, the results were reversed, which may have been related to different interventions. Compared with nutritional support, exercise training can improve lower-limb muscle strength significantly in a short time. Due to the small

Certain	Certainty Assessment						N≙ of	of		Effect	Certainty	Certainty Importance
							Patients	nts				
№ of Studies	Study Design	Risk of Bias	Risk of Inconsistency Bias	Indirectness	Imprecision	Other Considerations	S	ບູ ບ	Relative (95% CI)	Absolute (95% Cl)		
6MWT	-											
6	Randomized Serious ^a trials	Serious ^a	Serious ^b	Not serious	Not serious	None	180	139	ı	MD 69.64 higher (40.26 higher to 99.01 higher)		IMPORTANT
SGRQ												
£	Randomized Serious ^a trials	Serious ^a	Not serious	Not serious	Not serious	None	144	103	ı	MD 12.77 lower (16.03 lower to 9.5 lower)	⊕⊕⊕⊖ MODERATE	CRITICAL
Notes: ^a lacl Abbreviati	Notes: ^a lack of blinding and concealment of allocation are not Abbreviations: Cl, Confidence interval; MD, Mean difference.	ncealment of a interval; MD	Notes: ^a lack of blinding and concealment of allocation are not clear. ^b High heterogeneity (1 ² >50%). Abbreviations: Cl, Confidence interval: MD, Mean difference.	ır. ^b High heterogen€	eity (1 ² >50%).			1				

Zhang et al

sample size of the included studies, this result needs to be verified further.

Studies have focused more on the role of PR in improving the QoL and exercise tolerance of AECOPD patients. The prevalence of mortality and hospital readmission are convincing endpoints to judge the efficacy of treatment methods. Studies have shown that PR during hospitalization can reduce the prevalence of hospital readmission, but cohort studies have suggested that, for some patients, this approach may increase the risk of future hospitalization.²⁶ Healthcare facilities should provide early PR and pay attention to its long-term effect in AECOPD patients, and whether it can reduce the prevalence of hospital readmission and mortality.

Our study had three main advantages compared with previous studies. First, this is the first systematic review to analyze the efficacy and safety of early PR started <3 days of hospitalization in patients with AECOPD. Second, articles were from seven countries on four continents, which reduces any regional bias. Third, we used a combination of electronic retrieval and manual retrieval without language restrictions, which reduced the selection bias.

Our study had four main limitations in. First, evaluation of the quality of each study based on Review Manager 5.3 is a subjective process. Although the quality of each study was evaluated by two researchers independently and checked by a third researcher, some biases would have remained. Second, the studies we included involved PR being initiated <3 days of hospital admission; we did not compare the effects with studies conducted >3 days after AECOPD. Third, the number of studies that could undergo meta-analysis for each outcome indicator was limited, so funnel plots were not suitable, hence we could not fully assess publication bias. Fourth, the effect of a single intervention for early PR was not evaluated.

Conclusions

PR within three days of hospitalization may increase the exercise capacity and improve the QoL of patients with AECOPD. Our meta-analysis did not show that early PR shortened the DoHS or improve the QMS and 5STS of AECOPD patients. Only one serious adverse event was reported in the experimental group, which was not associated with early PR. Our meta-analysis demonstrates that early PR during hospitalization is safe and efficacious, but the results

Outcomes	Deletion		Result
6MWD	Öncü E 2017	χ2=44.06, <i>P</i> <0.0001;1 ² =91%	MD76.96; 95% CI [41.13, 112.79]
	Knaut C 2020	χ2=34.12, P<0.0001;l ² =88%	MD86.50; 95% CI [45.38, 127.61]
	He M 2015	χ2=43.98, P<0.0001;l ² =91%	MD83.66; 95% CI [33.47, 133.86]
	Greulich T 2014	χ2=41.63, P<0.0001;l ² =90%	MD66.34; 95% CI [35.68, 97.01]
	Borges RC 2014	χ2=28.05, <i>P</i> <0.0001;l ² =86%	MD55.45; 95% CI [29.10, 81.80]
	Lu H 2020	χ2=26.21, <i>P</i> <0.0001;l ² =85%	MD55.44; 95% CI [28.91, 81.97]
SGRQ	Borges RC 2014	χ2=0.90, <i>P</i> =0.34;l ² =0%	MD-13.13; 95% CI [-16.52, -9.74]
	Greulich T 2014	χ2=0, <i>P</i> =0.99;I ² =0%	MD-8.35; 95% CI [-16.16, -0.53]
	Knaut C 2020	χ2=0.73, <i>P</i> =0.39;l ² =0%	MD-13.25; 95% CI [-16.69, -9.81]
DoHS	Borges RC 2014	χ2=3.55, <i>P</i> =0.74;l ² =0%	MD0.32; 95% CI [-0.03, 0.68]
	Greulich T 2014	χ2=6.92, <i>P</i> =0.33;l ² =13%	MD0.27; 95% CI [-0.08, 0.62]
	Osadnik CR 2014	χ2=6.91, <i>P</i> =0.33;l ² =13%	MD0.26; 95% CI [-0.09, 0.61]
	Lu H 2020	χ2=4.86, <i>P</i> =0.56;l ² =0%	MD-0.22; 95% CI [-0.97, 0.52]
	Lopez Lopez L 2018	χ2=6.90, <i>P</i> =0.33; I ² I ² =13%	MD0.26; 95% CI [-0.09, 0.61]
	Torres-Sánchez I 2018	χ2=6.80, <i>P</i> =0.34;l ² =12%	MD0.25; 95% CI [-0.11, 0.61]
	Lopez Lopez L2020	χ2=5.89, <i>P</i> =0.44;l ² =0%	MD0.31; 95% CI [-0.05,0.68]
	Knaut C 2020	χ2=5.00, <i>P</i> =0.54;l ² =0%	MD0.29; 95% CI [-0.06, 0.64]
QMS	Vermeeren MA 2004	χ2=0.22, <i>P</i> =0.64;l ² =0%	MD28; 95% CI [13.30,42.69]
	Torres-Sánchez I 2018	χ2=5.49, <i>P</i> =0.02;l ² =82%	MD14.43; 95% CI [-16.80,45.67]
	Lopez Lopez L 2019	χ2=6.92, <i>P</i> =0.009;l ² =86%	MD11.81; 95% CI [-12.15,35.78]
5 STS	Greulich T 2014	χ2=0.66, <i>P</i> =0.72;l ² =0%	MD-2.45; 95% CI [-7.79, 2.89]
	Lopez Lopez L 2018	χ2=2.17, <i>P</i> =0.34;l ² =8%	MD-3.36; 95% CI [-8.59, 1.86]
	Lopez Lopez L 2019	χ2=1.33, <i>P</i> =0.52;l ² =0%	MD-6.30; 95% CI [-13.01, 0.42]
	Lopez Lopez L 2020	χ2=2.41, <i>P</i> =0.30;l ² =17%	MD-4.20; 95% CI [-10.10,1.71]

Table 3 Results of Sensitivity Analysis

should be interpreted prudently and dialectically, and the role of early PR in AECOPD needs further exploration.

Acknowledgments

The authors really appreciate the help of people from Henan University of Traditional Chinese Medicine.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This article was sponsored by The Key Program of Specialized Research for National TCM Clinical Research Bases from Traditional Chinese Medicine Administration of Henan Province, China (Grant No. 2018JDZX007) and the construction project of the characteristic backbone discipline of Chinese medicine in Henan province, China (Grant No. STG-ZYXKY -2020005). The authors report no conflicts of interest in this work.

References

- GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392 (10159):1736–1788.
- GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Respir Med.* 2017;5 (9):691–706.
- Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2020). Available from: https://goldcopd.org/gold-reports/. Accessed December 8, 2021.
- Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study[J]. *Lancet.* 2018;391 (10131):1706–1717.
- Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. *Lancet*. 2007;370(9589):786–796.
- Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. *Eur Respir J.* 2017;49(3):1600791.
- Montagnani A, Mathieu G, Pomero F, et al. Hospitalization and mortality for acute exacerbation of chronic obstructive pulmonary disease (COPD): an Italian population-based study. *Eur Rev Med Pharmacol Sci.* 2020;24(12):6899–6907.
- Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. *Thorax*. 2005;60(11):925–931.
- 9. Bhatt SP, Wells JM, Iyer AS, et al. Results of a medicare bundled payments for care improvement initiative for chronic obstructive pulmonary disease readmissions. *Ann Am Thorac Soc.* 2017;14(5):643–648.
- MacLeod M, Papi A, Contoli M, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: diagnosis, treatment, prevention and disease impact. *Respirology*. 2021;26(6):532–551.
- Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP, et al. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. *Eur Respir J.* 2011;37(3):508–515.
- Vogelmeier, Claus F, Criner, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. Am J Respir Crit Care Med. 2017;195(5):557–582.
- Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med.* 2013;187(4):347–365.
- 14. Dobler CC, Morrow AS, Farah MH, et al. Pharmacologic and Nonpharmacologic Therapies in Adult Patients with Exacerbation of COPD: A Systematic Review. *Report No.:* 19(20)-EHC024-EF. Rockville (MD): Agency for Healthcare Research and Quality (US); 2019.
- Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. *Am J Respir Crit Care Med.* 2013;188(8):e13–64.
- Lightowler JV, Wedzicha JA, Elliott MW, et al. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: cochrane systematic review and meta-analysis. *BMJ*. 2003;326(7382):185.

- 17. Puhan MA, Scharplatz M, Troosters T, et al. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality – a systematic review. *Respir Res.* 2005;6 (1):54.
- Puhan M, Scharplatz M, Troosters T, et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2009;1:CD005305.
- Tang CY, Taylor NF, Blackstock FC. Chest physiotherapy for patients admitted to hospital with an acute exacerbation of chronic obstructive pulmonary disease (COPD): a systematic review. *Physiotherapy*. 2010;96(1):1–13.
- Hill K, Patman S, Brooks D. Effect of airway clearance techniques in patients experiencing an acute exacerbation of chronic obstructive pulmonary disease: a systematic review. *Chron Respir Dis*. 2010;7(1):9–17.
- Walters JA, Turnock AC, Walters EH, et al. Action plans with limited patient education only for exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2010;5:CD005074.
- Puhan MA, Gimeno-Santos E, Scharplatz M, et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2011;10:CD005305.
- 23. Reid WD, Yamabayashi C, Goodridge D, et al. Exercise prescription for hospitalized people with chronic obstructive pulmonary disease and comorbidities: a synthesis of systematic reviews. *Int J Chron Obstruct Pulmon Dis.* 2012;7:297–320.
- 24. Harrison SL, Janaudis-Ferreira T, Brooks D, et al. Self-management following an acute exacerbation of COPD: a systematic review. *Chest*. 2015;147(3):646–661.
- Echevarria C, Brewin K, Horobin H, et al. Early supported discharge/ hospital at home for acute exacerbation of chronic obstructive pulmonary disease: a review and meta-analysis. *COPD*. 2016;13 (4):523–533.
- 26. Moore E, Palmer T, Newson R, et al. Pulmonary rehabilitation as a mechanism to reduce hospitalizations for acute exacerbations of COPD: a systematic review and meta-analysis. *Chest.* 2016;150 (4):837–859.
- Puhan MA, Gimeno-Santos E, Cates CJ, et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2016;12(12):CD005305.
- Howcroft M, Walters EH, Wood-Baker R, et al. Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2016;12(12):CD005074.
- Ryrsø CK, Godtfredsen NS, Kofod LM, et al. Lower mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic review and meta-analysis. *BMC Pulm Med.* 2018;18(1):154.
- 30. Torres-Sánchez I, Cruz-Ramírez R, Cabrera-Martos I, et al. Results of physiotherapy treatments in exacerbations of chronic obstructive pulmonary disease: a systematic review. *Physiother Can.* 2017;69 (2):122–132.
- Lindenauer PK, Stefan MS, Pekow PS, et al. Association between initiation of pulmonary rehabilitation after hospitalization for COPD and 1-year survival among medicare beneficiaries. *JAMA*. 2020;323 (18):1813–1823.
- Burtin C, Decramer M, Gosselink R, et al. Rehabilitation and acute exacerbations. *Eur Respir J.* 2011;38(3):702–712.
- 33. Machado A, Matos Silva P, Afreixo V, et al. Design of pulmonary rehabilitation programmes during acute exacerbations of COPD: a systematic review and network meta-analysis. *Eur Respir Rev.* 2020;29(158):200039.
- 34. Greening NJ, Williams JE, Hussain SFet al. An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial. *BMJ*. 2014;349:g4315.
- 35. Valenzuela PL, Saco-Ledo G, Rivas-Baeza B, et al. Safety of in-hospital early rehabilitation in chronic obstructive pulmonary disease exacerbations: a systematic review and meta-analysis. *Ann Phys Rehabil Med.* 2021;65:101528.

- Oliveira AL, Marques AS. Outcome measures used in pulmonary rehabilitation in patients with acute exacerbation of chronic obstructive pulmonary disease: a systematic review. *Phys Ther.* 2018;98 (3):191–204.
- 37. Higgins J, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions (Version 6.2). The cochrane collaboration; 2021. Available from: https://training.cochrane.org/ handbook. Accessed December 8, 2021.
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.
- 39. Review Manager (RevMan) [Computer program], "Version 5.3. Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration; 2014.
- 40. Guyatt GH, Oxman AD, Vist GE, et al. GRADE Working Group. GRADE: An Emerging Consensus on Rating Quality of Evidence and Strength of Recommendations. BMJ. 2008;336(7650):924–926.
- 41. Vermeeren MA, Wouters EF, Geraerts-Keeris AJ, et al. Nutritional support in patients with chronic obstructive pulmonary disease during hospitalization for an acute exacerbation; a randomized controlled feasibility trial. *Clin Nutr.* 2004;23(5):1184–1192.
- 42. Tang CY, Blackstock FC, Clarence M, et al. Early rehabilitation exercise program for inpatients during an acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trial. *J Cardiopulm Rehabil Prev.* 2012;32(3):163–169.
- 43. Greulich T, Nell C, Koepke J, et al. Benefits of whole body vibration training in patients hospitalised for COPD exacerbations a randomized clinical trial. *BMC Pulm Med.* 2014;14(1):60.
- 44. Osadnik CR, McDonald CF, Miller BR, et al. The effect of positive expiratory pressure (PEP) therapy on symptoms, quality of life and incidence of re-exacerbation in patients with acute exacerbations of chronic obstructive pulmonary disease: a multicentre, randomised controlled trial. *Thorax*. 2014;69(2):137–143.
- 45. Borges RC, Carvalho CR. Impact of resistance training in chronic obstructive pulmonary disease patients during periods of acute exacerbation. *Arch Phys Med Rehabil.* 2014;95(9):1638–1645.
- 46. He M, Yu S, Wang L, et al. Efficiency and safety of pulmonary rehabilitation in acute exacerbation of chronic obstructive pulmonary disease. *Med Sci Monit.* 2015;21:806–812.
- 47. Torres-Sánchez I, Valenza MC, Cabrera-Martos I, et al. Effects of an exercise intervention in frail older patients with chronic obstructive pulmonary disease hospitalized due to an exacerbation: a randomized controlled trial. *COPD*. 2017;14(1):37–42.
- 48. Öncü E, Zincir H. The effect of transcutaneous electrical nerve stimulation in patients with acute exacerbation of chronic obstructive pulmonary disease: randomised controlled trial. *J Clin Nurs.* 2017;26 (13–14):1834–1844.

- 49. Torres-Sánchez I, Valenza MC. Cebriá I Iranzo MDÀ, et al. Effects of Different Physical Therapy Programs on Perceived Health Status in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Patients: a Randomized Clinical Trial. Disabil Rehabil. 2018;40 (17):2025–2031.
- 50. Lopez Lopez L, Granados Santiago M, Donaire Galindo M, et al. Efficacy of combined electrostimulation in patients with acute exacerbation of COPD: randomised clinical trial. *Med Clin (Barc)*. 2018;151(8):323–328.
- 51. Lopez-Lopez L, Torres-Sanchez I, Rodriguez-Torres J, et al. Randomized feasibility study of twice a day functional electrostimulation in patients with severe chronic obstructive pulmonary disease hospitalized for acute exacerbation. *Physiother Theory Pract*. 2019;37:1–8.
- 52. Lopez-Lopez L, Valenza MC, Rodriguez-Torres J, et al. Results on health-related quality of life and functionality of a patient-centered self-management program in hospitalized COPD: a randomized control trial. *Disabil Rehabil.* 2020;42(25):3687–3695.
- 53. Knaut C, Bonfanti Mesquita C, Dourado VZ, et al. Evaluation of inflammatory markers in patients undergoing a short-term aerobic exercise program while hospitalized due to acute exacerbation of COPD. Int J Inflam. 2020;2020:6492720.
- 54. Lu H, Liu N, Hu JY, et al. The effectiveness, safety and compliance of Zheng's supine rehabilitation exercise as a rehabilitation programme among elderly patients with AECOPD. *Clin Respir J.* 2020;14(6):533–540.
- Holland AE, Nici L. The return of the minimum clinically important difference for 6-minute-walk distance in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2013;187(4):335–336.
- 56. Redelmeier DA, Bayoumi AM, Goldstein RS, et al. Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. *Am J Respir Crit Care Med.* 1997;155 (4):1278–1282.
- Weldam SW, Schuurmans MJ, Liu R, et al. Evaluation of Quality of Life instruments for use in COPD care and research: a systematic review. *Int J Nurs Stud.* 2013;50(5):688–707.
- Janson C, Marks G, Buist S, et al. The impact of COPD on health status: findings from the BOLD study. *Eur Respir J.* 2013;42 (6):1472–1483.
- 59. Evans RA, Kaplovitch E, Beauchamp MK, et al. Is quadriceps endurance reduced in COPD?: a systematic review. *Chest.* 2015;147 (3):673–684.
- 60. Alcazar J, Losa-Reyna J, Rodriguez-Lopez C, et al. The sit-to-stand muscle power test: an easy, inexpensive and portable procedure to assess muscle power in older people. *Exp Gerontol.* 2018;112:38–43.

International Journal of Chronic Obstructive Pulmonary Disease

Dovepress

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal